Page last updated: 2024-09-03

3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate and Adamantiades-Behcet Disease

3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate has been researched along with Adamantiades-Behcet Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cantarini, L; Capecchi, PL; Castrichini, M; Franceschini, R; Galeazzi, M; Gamberucci, A; Gianchecchi, E; Hammoud, M; Laghi-Pasini, F; Lazzerini, PE; Montilli, C; Moramarco, A; Natale, M; Ricci, G; Selvi, E; Zimbone, S1

Other Studies

1 other study(ies) available for 3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate and Adamantiades-Behcet Disease

ArticleYear
The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α.
    European journal of immunology, 2014, Volume: 44, Issue:1

    Topics: Adenosine Triphosphate; Adult; Behcet Syndrome; Biological Transport, Active; Calcium; Cells, Cultured; Female; Gene Expression Regulation; Humans; Immunity, Innate; Interleukin-1beta; Ion Transport; Lipopolysaccharides; Macrophages; Male; Monocytes; Platelet Aggregation Inhibitors; Purinergic P2X Receptor Agonists; Receptors, Purinergic P2X7; Tumor Necrosis Factor-alpha

2014